Tuesday, November 14, 2023 at 2-3 pm ET                 Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Urinary tract infections (UTIs) are among the most common bacterial infections encountered in the ambulatory care setting in the United States. Rates of E. Coli resistance to some commonly prescribed treatments for community-acquired uncomplicated UTIs are high in some regions in the US, attributing to treatment failure. Recent evidence has shown that approximately 12% to 17% of patients diagnosed with an uncomplicated UTI experienced failure to empiric treatment for various reasons. Understanding those factors that may place a patient at higher risk of treatment failure can help to guide appropriate treatment. This program will provide disease education for population-based decision makers to inform on AMR in uncomplicated UTI, risk of treatment failure, and clinical and economic consequences of treatment failure.

Learning Objectives

• Define uncomplicated UTI and review current management.
• Inform on rates of antimicrobial resistance to common pathogens in community-acquired uncomplicated UTI.
• Describe risk factors for treatment failure in uncomplicated UTI and clinical and economic consequences of failure.
• Discuss how antimicrobial stewardship is an important part of addressing AMR challenges.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.